Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

NCT00648037 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Disease
Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma

Interventions

DRUG: Rituximab

Sponsor

Memorial Sloan Kettering Cancer Center